Bank of New York Mellon Corp Buys 150 Shares of BioNTech SE (NASDAQ:BNTX)

Bank of New York Mellon Corp lifted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,677 shares of the company’s stock after acquiring an additional 150 shares during the quarter. Bank of New York Mellon Corp’s holdings in BioNTech were worth $419,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after buying an additional 300 shares during the period. AlphaCentric Advisors LLC acquired a new position in shares of BioNTech in the 4th quarter valued at about $168,000. Harbor Advisors LLC bought a new stake in shares of BioNTech during the 3rd quarter valued at about $238,000. Freedom Investment Management Inc. acquired a new stake in BioNTech during the third quarter worth approximately $243,000. Finally, Retireful LLC bought a new stake in BioNTech in the fourth quarter worth approximately $260,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. BMO Capital Markets upped their price target on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Morgan Stanley cut their target price on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a report on Tuesday, March 11th. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target for the company. Canaccord Genuity Group restated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Finally, Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $143.73.

BioNTech Stock Down 0.5 %

NASDAQ BNTX opened at $94.95 on Friday. The stock’s 50-day moving average price is $111.41 and its 200-day moving average price is $113.55. The company has a market capitalization of $22.79 billion, a P/E ratio of -45.21 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the prior year, the business posted $1.90 EPS. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities research analysts predict that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.